CXCL12 and plasma cell myeloma: The SDF-1/CXCR4 inhibitor showed on moderate effects on the efficacy of BZM when treating multiple myeloma developed in both normal and myeloma-associated bone marrow stromal cell microenvironments in terms of both the shrinkage of total tumor size (red contour lines in Figure 7 a and b, respectively) and the decrease of MIC populations (red contour lines in Figure 7 c and d, respectively).